Obesity Medicine Association Announced as Primary Educational Partner of the American Board of Obesity Medicine
Denver, Colorado--(Newsfile Corp. - August 19, 2026) - The Obesity Medicine Association (OMA) is honored to announce that they have been named one of the first Primary Educational Partners (PEPs) of the American Board of Obesity Medicine (ABOM). PEPs are organizations approved by ABOM to offer Core Obesity Medicine CME credit to physicians applying for obesity medicine certification through their Continuing Medical Education (CME) pathway. The partnership program was designed as
Soins de santé et hôpitaux, Santé
2026-08-19 9:00 AM EDT | Obesity Medicine Association
Rhelion Life Sciences Announces Appointment of Samiuddin Khaja as CFO
Toronto, Ontario--(Newsfile Corp. - August 19, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company"), an Ontario-based organization advancing innovation and research within the legal psychedelic sector, is pleased to announce the appointment of Samiuddin Khaja as Chief Financial Officer ("CFO") effective immediately. The appointment comes as Rhelion continues its evolution into a focused, research-led life sciences company following the a
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-08-19 8:14 AM EDT | Rhelion Life Sciences Corp.
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced the appointment of Mahan Chehrenama, DO, as Chief Medical Officer. Dr. Chehrenama will lead clinical development for BETR-001, the Company's non-hallucinogenic neuroplastogen advancing toward an Investigational New Drug (IND) appli
2026-08-19 8:00 AM EDT | BetterLife Pharma Inc.
Charlotte's Web Launches Route CBD to Support Californians Who Depend on Full-Spectrum Hemp CBD
Louisville, Colorado--(Newsfile Corp. - August 19, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF), the market leader in hemp extract wellness products, today announced the launch of Route CBD, a multi-city advocacy initiative designed to create access and raise awareness of the growing crisis facing Californians who have lost access to trusted full spectrum hemp CBD products.
2026-08-19 7:07 AM EDT | Charlotte's Web Holdings, Inc.
FloraWorks Advances Patented TruCBN(TM) Platform with Peer-Reviewed Safety Publication and Internal GRAS Conclusion
Portland, Oregon--(Newsfile Corp. - August 18, 2026) - FloraWorks Holdings Inc. ("FloraWorks") today announced significant new scientific and regulatory milestones for TruCBN™, its proprietary high-purity cannabinol (CBN) ingredient, further advancing the company's patented CBN platform. TruCBN™ is produced from hemp-derived CBD using FloraWorks' patented controlled oxidation process, protected under U.S. Patent No. 12,371,412 B2. CBN forms naturally in hemp through o
Technologies, Cannabis, Santé, Producteurs de cannabis
2026-08-18 11:00 AM EDT | FloraWorks
TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies
Toronto, Ontario--(Newsfile Corp. - August 18, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-08-18 7:00 AM EDT | TempraMed Technologies Ltd.
Custom Health Achieves 70% Increase in Quarterly Revenue in Q2-2026 and Advances Medication Management Platform with Evergreen Pharmacy and Spencer Health Solutions Acquisitions
For the three months ended June 30, 2026, Custom Health achieved quarterly revenue of US$7.4 million, an increase of 70% from Q2-2025. The results reflect the acquisition of InnovativeRx during the period. The equity pickup for IRX accounts for an acquisition date of June 5, 2026. Proforma Revenue for the combined entity for the 3 months ended June 30, 2026 is US$14.3 million(1). Subsequent to quarter-end, Custom Health entered into a binding letter
Technologies, Pharmaceutique, Santé
2026-08-17 6:07 PM EDT | Custom Health Holdings Inc.
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Montreal, Quebec--(Newsfile Corp. - August 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Ryan Simms, PhD, as Chief Operating Officer ("COO") and Head of Radiopharmaceutical Programs, strengthening the Company's leadership and deve
Biotechnologies, Pharmaceutique, Santé
2026-08-17 3:15 AM EDT | Defence Therapeutics Inc.
Hanf.com Transaction Advances as Neural Therapeutics Receives CSE Conditional Approval
Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") is pleased to announce that it has received conditional approval from the Canadian Securities Exchange (the "CSE") for the listing of the Company's shares following completion of its previously announced fundamental change transaction involving CWE European Holdings Inc. ("CWE"), which operates the Hanf.com business in Germany (
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-08-14 5:01 PM EDT | Neural Therapeutics Inc.
Rhelion Life Sciences Signs Agreement with University Health Network for Randomized Clinical Trial of Psilocybin in Parkinson's Disease Depression
Toronto, Ontario--(Newsfile Corp. - August 14, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psy
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-08-14 8:14 AM EDT | Rhelion Life Sciences Corp.
Cosmo Announces SIX Ticker Symbol Change to "CMHC"
Dublin, Ireland--(Newsfile Corp. - August 14, 2026) - Cosmo N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that it will change its ticker symbol on the SIX Swiss Stock Exchange from “COPN” to “CMHC”. This change is expected to take effect at the opening of trading on Monday, August 17, 2026. The new ticker symbol,
Soins de santé et hôpitaux, Santé
2026-08-14 1:22 AM EDT | Cosmo Pharmaceuticals N.V.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the first quarter of fiscal year 2027 ended June 30, 2026 ("First Quarter"). Consolidated revenues for the three-month period ending June 30, 2026, were $32.4 million, a decrease of $7.9 million or approximately 19.5% as compared to the same period of the pri
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-08-13 4:11 PM EDT | Elite Pharmaceuticals, Inc.
Akanda's First Towers & Fiber Increases Recurring Revenue with Completion of 200 KM Fiber Network
Toronto, Ontario--(Newsfile Corp. - August 13, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), an emerging telecommunications infrastructure developer in Mexico, today announced an update on recent operational milestones and expansion progress, underscoring its continued growth in telecommunications infrastructure. Core Business and Tower Operations FTF maintains a portfolio of 28 cellular
Cannabis, Santé, Cultivateurs de cannabis, Producteurs de cannabis
2026-08-13 4:05 PM EDT | Akanda Corp
Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half
Winter Park, Florida--(Newsfile Corp. - August 13, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and advanced clinical services, today announced financial results for the second quarter ended June 30, 2026, as reported in its Form 10-Q filed with the Securities and Exchange Commission.
Soins de santé et hôpitaux, Santé
2026-08-13 12:07 PM EDT | Adia Med Inc.
Charlotte's Web Reports Second Quarter 2026 Financial Results
Louisville, Colorado--(Newsfile Corp. - August 13, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) ("Charlotte's Web" or the "Company"), a botanical wellness innovation company and the market leader in cannabidiol (CBD) hemp extract wellness products, today announced results for the quarter ended June 30, 2026. All amounts are expressed in U.S. dollars unless otherwise indicated. "The second quarter fundamentally changed Charlotte's Web's financial position.
2026-08-13 7:07 AM EDT | Charlotte's Web Holdings, Inc.
LIS Technologies Announces $6.2M Acquisition of the 37,800sq-ft K-1580 Facility at the Historic Heritage Center in Oak Ridge, Tennessee to Expand its Medical and Stable Isotope and Nuclear Fuel Cycle Initiatives
Oak Ridge, Tennessee--(Newsfile Corp. - August 12, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a developer of proprietary advanced laser technology and the only USA-origin and patented laser uranium enrichment company, is pleased to announce that it has expanded its presence in Oak Ridge, Tennessee's historic Heritage Center and K-25 Enrichment Site with the acquisition of the K-1580 Building, a prominent, newly-renovated, three-level, 37,803 square-foot facility, for a to
Technologies, Mines et métaux, Énergie, Santé
2026-08-12 8:59 AM EDT | LIS Technologies Inc.
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell™ (ACP-01) longevity clinical trial. The study is designed to investigate whether Hemostemix' VesCell™ can improve measurable dimensions of longevity including cardiovascular h
Biotechnologies, Pharmaceutique, Santé
2026-08-12 8:23 AM EDT | Hemostemix Inc.
Experience Onward Acquires 36 Acre Colorado Property to Launch Onward Ranch, a Legal Psilocybin and Wellness Retreat Destination
Denver, Colorado--(Newsfile Corp. - August 11, 2026) - Experience Onward, founded by former NHL player and two time Stanley Cup champion Daniel Carcillo, today announced the acquisition of a private, 36 acre mountain property in Colorado that is now progressing through the state licensing process to become a legal psilocybin retreat destination. Named Onward Ranch, the property is being developed as a first of its kind residential retreat environment designed to bring legal, regu
2026-08-11 9:00 AM EDT | Experience Onward
Adia Med Partners with Full Sail University; CEO Larry Powalisz to Present Company and Explore Student Assistance with SEO, Social Media, and Marketing
Winter Park, Florida--(Newsfile Corp. - August 11, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced a new educational partnership with Full Sail University. As part of the collaboration, Adia Med Chief Executive Officer Larry Powalisz will present the company at Full Sail's Auditorium on August 13, 2026, at 1:00 p.m. to both in-person students and those joining live online.
Soins de santé et hôpitaux, Santé
2026-08-11 8:00 AM EDT | Adia Med Inc.
ONE HEMP Welcomes Senate Continuing Resolution Passage, Calls for Clear Distinctions in Hemp Policy
Washington, D.C.--(Newsfile Corp. - August 11, 2026) - ONE HEMP welcomed the Senate's passage of a continuing resolution extending naturally-occurring hemp product ban until December 11, preventing a broad restriction on full-spectrum hemp products from taking effect on November 12 and providing Congress additional time to advance sound, science-based legislation. The extension creates an opportunity for lawmakers to develop a regulatory framework that protects consumers while pr
2026-08-11 7:23 AM EDT | OneHemp